Study finds common breast cancer treatments may speed aging process

Charles Geyer named associate group chair of NRG Oncology

The NRG Oncology Group Chairs created the position of associate group chair and selected Charles E. Geyer to fill the position, effective immediately. He will serve alongside the three NRG Oncology group chairs, Quynh-Thu Le, Robert Mannel, and Norman Wolmark.

February 21, 2025

Vol.51 No.07

In Brief

UCLA awarded $1.72M NIH grant to train brain cancer scientists

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have been awarded a $1.72 million grant from NIH to support the Neuro-Oncology Translational Research Training Program, an initiative designed to train the next generation of brain tumor scientists and physician-scientists.

February 07, 2025

Vol.51 No.05

Clinical Roundup

UCLA-led study establishes link between early side effects from prostate cancer radiation and long-term side effects

Men undergoing radiation therapy for prostate cancer who experience side effects early in treatment may face a higher risk of developing more serious long-term urinary and bowel health issues, according to a study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center.

February 07, 2025

Vol.51 No.05

Clinical Roundup

Genentech’s Itovebi demonstrated OS benefit in advanced breast cancer, phase III trial finds

Genentech announced positive topline results from the overall survival analysis of the phase III INAVO120 study investigating Itovebi (inavolisib) in combination with palbociclib (Ibrance) and fulvestrant for people with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.

January 31, 2025

Vol.51 No.04

Drugs & Targets

FDA approves Enhertu as first HER2-directed therapy for breast cancer

FDA approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by the FDA approved test, that has progressed on one or more endocrine therapies in the metastatic setting.

January 31, 2025

Vol.51 No.04

Conversation with The Cancer Letter Real-world Evidence

RWD company documents baseline trends in women’s cancers before Trump’s policy changes

The U.S. Supreme Court’s June 2022 decision to overturn Roe v. Wade has implications that reach far beyond access to reproductive health care services in the 41 states that ban or restrict access to abortion.

January 24, 2025

Vol.51 No.03

By Claire Marie Porter